Afabicin is under clinical development by Debiopharm International and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Afabicin’s likelihood of approval (LoA) and phase transition for Skin And Skin Structure Infections (SSSI) Caused By Bacteria took place on 27 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Afabicin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Debio-1450 (previously AFN-1720) is under development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), Staphylococcus infections like methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), and bone and Joint infections (osteomyelitis). The drug candidate is administered intravenously and orally in the form of the solution and capsule. Debio-1450 is a prodrug of AFN-1252 (Debio-1452), It acts by targeting enoyl-acyl carrier protein reductase (FabI).
Debiopharm International overview
Debiopharm International, a subsidiary of Debiopharm Group, focuses on development and manufacture of drugs for oncology and bacterial infections. The company offers Oxaliplatin and Triptorelin drugs. It is investigating proteins, peptides and small molecules to treat cancers, solid tumors, bone and joint infections, and gastrointestinal disorders. Debiopharm is headquartered in Lausanne, Switzerland.
Quick View Afabicin LOA Data
|Highest Development Stage|